SCHEMBL6071699

SCHEMBL6071699

Fc1ccc(Nc2ccnc3ccccc23)cc1Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.68
PTK6 Q13882 1/20 0.64
EGFR P00533 3/20 0.64
TGFBR1 P36897 2/20 0.60
CD38 P28907 1/20 0.60
KDR P35968 6/20 0.55
ACP1 P24666 1/20 0.54
ERBB2 P04626 1/20 0.53
ABCG2 Q9UNQ0 1/20 0.53
HTT P42858 1/20 0.52
DNMT1 P26358 1/20 0.51
DNMT3A Q9Y6K1 1/20 0.51
RIPK2 O43353 2/20 0.50
GAK O14976 1/20 0.50
COQ8A Q8NI60 1/20 0.50
NLK Q9UBE8 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C8 P10632 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4961504 0.87 CD38 (0.61) FADS1PTK6EGFRTGFBR1CD38
SCHEMBL4740968 0.85 CD38 (0.65) FADS1PTK6EGFRTGFBR1CD38
SCHEMBL30307426 0.83 FADS1 (0.60) FADS1EGFRTGFBR1KDRERBB2
SCHEMBL23117519 0.83 CD38 (0.62) FADS1PTK6EGFRCD38RIPK2
SCHEMBL6071379 0.82 PTK6 (0.59) FADS1PTK6EGFRTGFBR1CD38
SCHEMBL30307407 0.82 FADS1 (0.70) FADS1EGFRKDRERBB2HTT
SCHEMBL4787800 0.82 CD38 (0.64) FADS1PTK6EGFRCD38KDR
SCHEMBL4740569 0.81 FADS1 (1.00) FADS1PTK6EGFRTGFBR1KDR
SCHEMBL6071332 0.81 ACP1 (0.63) PTK6EGFRACP1ABCG2
SCHEMBL15673390 0.79 ERBB2 (0.66) FADS1EGFRTGFBR1KDRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CSNK1A1L, CDKL1 FADS1 3286/4885PTK6 180/4885EGFR 4122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.